Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Dialectic Therapeutics","sponsor":"Cancer Prevention & Research Institute of Texas","pharmaFlowCategory":"D","amount":"$3.0 million","upfrontCash":"Undisclosed","newsHeadline":"Dialectic Therapeutics Receives $3 Million Seed Award for Product Development Research","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"February 2020","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Dialectic Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dialectic Therapeutics Gets FDA Clearance of IND Application for Lead Antiapoptotic Protein Targeted Degradation (APTaD) Candidate DT2216","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling"}]

    Find Clinical Drug Pipeline Developments & Deals by Dialectic Therapeutics

    Menu

    Dialectic Therapeutics

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Dialectic Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Dialectic Therapeutics Gets FDA Clearance of IND Application for Lead Antiapoptotic Protein Targeted Degradation (APTaD) Candidate DT2216

              Details:

              In pre-clinical studies DT2216 selectively induces cancer cells to degrade B-cell lymphoma extra-large, or BCL-XL, stimulating the cells to commit suicide or become more susceptible to chemotherapy.

              Lead Product(s): DT2216

              Therapeutic Area: Oncology Product Name: DT2216

              Highest Development Status: IND Enabling Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 03, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Dialectic Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Dialectic Therapeutics Receives $3 Million Seed Award for Product Development Research

              Details:

              Dialectic will use the funding to further the development of its lead product candidate, DT2216.

              Lead Product(s): DT2216

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: IND Enabling Product Type: Undisclosed

              Partner/Sponsor/Collaborator: Cancer Prevention & Research Institute of Texas

              Deal Size: $3.0 million Upfront Cash: Undisclosed

              Deal Type: Funding February 26, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY